Thoracic radiotherapy with atezolizumab increased toxicity in extensive-stage small cell lung cancer
TREASURE found no survival benefit and higher serious toxicity with thoracic radiotherapy added to atezolizumab maintenance.
TREASURE found no survival benefit and higher serious toxicity with thoracic radiotherapy added to atezolizumab maintenance.
Immuno-Eclipse radiotherapy improved bulky tumor control in mice through natural killer and cytotoxic T-cell immunity.
Adding early stereotactic body radiotherapy to neoadjuvant chemoimmunotherapy was associated with median progression-free survival of 12.5 versus 6.6 months.
Radiotherapy increased tumor uptake of PDL1-targeted radionuclide therapy, while antibody co-dosing reduced splenic trapping and restored antitumor efficacy in mice.